Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?

Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company focused on developing medicines and vaccines using messenger RNA (mRNA) technology. Valued at a market cap of $18.4 billion, Moderna is best known for its global impact during the COVID-19 pandemic with its vaccine, Spikevax, and has since expanded its commercial portfolio with various other vaccines and medicines.

Moderna has staged a remarkable comeback, emerging as one of biotech's biggest winners over the past year. Shares of Moderna have rallied 106.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 22.2%. Moreover, on a YTD basis, the stock is up 93.3%, compared to SPX’s 13% rise.